The savings could rise significantly if more accurate diagnostic tests were available, the authors say.
The phenotypic tests measure nucleic acid in bacteria after exposure to antibiotics.
A computerized clinical support tool implemented at an academic medical center helped reduce rates of Clostridioides difficile testing without an associated increase in adverse events in patients whose tests were prevented, researchers from the University of Virginia (UVA) School of Medicine reported today in Open Forum Infectious Diseases.
As of Mar 2, the United States so far this year has recorded 12 measles cases from 7 jurisdictions, the Centers for Disease Control and Prevention (CDC) said in a Mar 12 monthly update. The totals reflect an increase of 7 cases and 2 jurisdictions since the CDC's last update on Feb 3.
A new study by researchers from Harvard TH Chan School of Public Health suggests that outpatient prescribing of penicillins is associated with rates of mortality with sepsis in older US adults.
The United Kingdom's Food Standards Agency (FSA) released two surveillance reports this week on antimicrobial resistance (AMR) in chicken meat.
The United Kingdom yesterday announced the launch of a partnership with Nigeria, worth £10.7 million, to fight antimicrobial resistance (AMR) by improving public health surveillance, upgrading laboratory equipment, and training technicians.
CARB-X today announced an award of up to $6.8 million to Pattern Bioscience of Austin, Texas, to develop a rapid identification and antimicrobial susceptibility test (ID/AST) for drug-resistant pathogens.
Imperial College London announced yesterday that it has won a €22.5 million ($25 million US) grant to work with researchers in 15 countries over 5 years to develop a rapid test to diagnose infectious diseases based on personalized gene signatures after taking the next 2 years to develop a library of gene signatures covering common infections and other diseases.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $1.5 million to Phase Genomics of Seattle, Washington, to develop a low-cost, culture-free platform for detecting antimicrobial resistance (AMR) genes.